Comparison
Dulaglutide vs. Hexarelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
923950-08-7
140703-51-1
Molecular weight
59670 g/mol
887.05 g/mol
Half-life
110 h
0.9 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
3
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
1